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ABSTRACT 
 
Cerebrospinal fluid (CSF) circulates through the brain and has a unique composition 
reflecting the biological processes of the brain. Identifying ageing CSF biomarkers 
can aid in understanding the ageing process and interpreting CSF protein changes in 
neurodegenerative diseases. In this study, ovine CSF proteins from young (1-2 year 
old), middle aged (3-6 year old) and old (7-10 year old) sheep were systemically 
studied. CSF proteins were labelled with iTRAQ tagging reagents and fractionated by 
2-dimensional high performance, liquid chromatography. Tryptic peptides were 
identified using MS/MS fragmentation ions for sequencing and quantified from 
iTRAQ reporter ion intensities at m/z 114, 115, 116 and 117. Two hundred thirty one 
peptides were detected, from which 143 proteins were identified. There were 52 
proteins with >25% increase in concentrations in the old sheep compared to the 
young. 33 of them increased >25% but <50%, 13 increased >50% but <1 fold, 6 
increased >1 fold [i.e. haptoglobin (Hp), haemoglobin, neuroendocrine protein 7B2, 
IgM, fibrous sheath interacting protein 1, vimentin]. There were 18 proteins with 
>25% decrease in concentrations in the old sheep compared to the young. 17 of them 
decreased >25% but <50%, and histone deacetylase 7 (HDAC7) was gradually 
decreased for over 80%. Glutathione S-transferase was decreased in middle aged CSF 
compared to both young and old CSF. The differential expressions of 3 proteins (Hp, 
neuroendocrine protein 7B2, IgM) were confirmed by immunoassays. These data 
expand our current knowledge regarding ovine CSF proteins, supply the necessary 
information to understand the ageing process in the brain and provide a basis for 
diagnosis of neurodegenerative diseases.  
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Highlights 
 
 CSF protein changes during normal ageing process  
 Seventy proteins were changed in concentration among different aged sheep 
CSF  
 A common ageing CSF biomarker identified to date is immunoproteins 
 Identifying ageing CSF biomarker help understand the ageing process in the 
brain   
 
Key words: ageing, CSF, biomarkers, proteomics, choroid plexus, neurodegenerative 
disease
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1. INTRODUCTION 
 
Cerebrospinal fluid (CSF) is a clear, colourless bodily fluid that circulates through the 
brain and communicates freely with the brain extracellular fluid. In adult humans, 
about two-thirds of CSF is secreted by the choroid plexus (CP) at the rate of about 
0.35-0.4 ml / min or 500-600 ml / day, while the remainder is from the extrachoroidal 
sources [1]. CSF has a unique composition that is different from the plasma, due to 
the presence of blood-brain barrier (BBB) and blood-CSF barrier (BCSFB), the active 
secretion at the CP and specific transport systems for moving substances between 
blood and CSF. In comparison to plasma ultrafiltrate, CSF contains higher 
concentrations of sodium, chloride, and magnesium and lower concentrations of 
glucose, proteins, amino acids, uric acid, potassium, bicarbonate, calcium and 
phosphate [2]. The CSF is in direct contact with the brain interstitial fluid, and the 
composition of the CSF therefore reflects biological processes occurring in the brain 
[3]. This understanding has led to an interest in the potential for discovering 
biomarkers within the CSF, which can be used to monitor brain function and aid in 
diagnosis of neurological diseases.  
 
During ageing, several structural, chemical, and functional changes occur in the brain. 
The weight and volume of both cerebral cortex and hippocampus reduce, and the 
ventricular system expands to fill the space vacated by the brain parenchyma [4]. In 
contrast, the CP in the lateral ventricles doubles in weight, leading to significant 
increase of the ratio of the CP and the brain in weight [5,6]. The CSF secretion by the 
CP is decreased, leading to a decreased overall turnover of CSF which can affect its 
protein composition.  
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There are few studies on the CSF biology during ageing in absence of any 
neurological diseases, and the drastically incomplete knowledge hinders us from 
understanding the ageing process in the brain. In this study, we systemically 
characterized age-related protein changes in ovine CSF using a gel free proteomic 
mass spectrometry (MS) approach with isobaric labelled samples (iTRAQ) 
techniques. The advantage of using sheep in this study is that adequate CSF samples 
of all age groups can be obtained, with facile control over gender selection and 
environmental factors. Furthermore, we have previous characterized the age-related 
changes in the CP structure and function in the sheep, and found that the secretion rate 
of the CP is decreased thus slowed overall CSF turnover, which contributed to the 
increased protein concentrations within the CSF with increasing age [6-10].  
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2. METHODS 
 
2.1. Sample collection 
Clun Forest strain adult female sheep aged between 1 and 10 year old were divided 
into 3 groups: young (aged 1-2 years); middle-aged (3-6 years) and old (7-10 years). 
Each group comprises 7 sheep. Sheep were anaesthetized with i.v. thiopentone sodium 
(20 mg.kg−1) and heparinised (20,000 IU heparin kg−1). CSF samples were collected 
from the cisterna magna by needle puncture [11]. Samples were spun at 10 000 g for 
10 min at 4 °C. CSF samples with any blood contamination determined by the 
presence of erythrocytes in the solution or precipitation were discarded. Supernatants 
were immediately stored at -80 °C until being analysed. All procedures were within 
the Home Office Scientific procedures Act, 1986 (HMSO, London, UK), and were 
approved by King’s College London research ethics committee. 
  
2.2. Sample preparation for MS analysis  
Equal volumes of CSF samples from seven individuals within each group were pooled 
to give a final volume of 80 l per age group. An internal standard (IS) was prepared 
by pooling equal amount of each sample from the analysis set. The pooled samples 
were then digested with sequencing grade porcine trypsin (Promega, 
Fitchburg, Wisconsin, USA) overnight at 37 °C, followed by reduction and alkylation 
steps performed according to the instructions outlined in the iTRAQ labelling kit (AB 
Sciex, Framingham, MA, USA). Following this, the digests were then dried down in a 
vacuum centrifuge and iTRAQ labelling carried out also according to instructions in 
the iTRAQ labelling kit. Each iTRAQ tag was assigned as follows: iTRAQ reagent 
114 for Young, 115 for Middle-age, 116 for Old and 117 for the IS.  
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Both MS and MS/MS analysis was performed on the fractionated peptides using an 
Applied Biosystems 4800 MALDI TOF/TOF mass spectrometer. The mass 
spectrometer was operated under control of 4000 Series Explorer v3.5.2 software 
(Applied Biosystems, Waltham, Massachusetts, USA). A total of 1000 shots per MS 
spectrum (no stop conditions) and 2500 shots per MS/MS spectrum (no stop 
conditions) were acquired. The following MS/MS acquisition settings were used: 
2KV operating mode with CID on and precursor mass window resolution set to 
300.00 (FWHM). Peak lists of MS and MS/MS spectra were generated using 4000 
Series Explorer v3.5.2 software and the following parameters were used after 
selective labelling of monoisotopic mass peaks: MS peak lists: S/N threshold 10, 
Savitzky Golay smoothing (3 points across peak (FWHM)), no baseline correction, 
MS/MS peak lists: S/N threshold 14; smoothing algorithm: Savitzky Golay, 
smoothing (7 points across peak (FWHM)). 
 
2.3. Quantitative MS analysis  
 
Liquid chromatography fractionation and subsequent MS analysis was conducted as 
described before [12]. Briefly, labelled tryptic peptides obtained from protein 
digestion were pooled and dissolved in 2.4 ml of SCX buffer A (10 mM phosphate, 
20% acetonitrile) and centrifuged at 15,000 × g for 5 min to remove any insoluble 
debris. The peptide mixture was loaded onto a Polysulphoethyl A column (4.6 mm × 
100 mm, 5 μm, 300 Å, PolyLC Inc.) using a flow rate of 800 μl / min. The bound 
sample was washed using SCX buffer A for approximately 20 min, until non-binding 
mixture components were removed (as determined by the UV traces returning to 
baseline levels). Peptides were then eluted at 400 μl / min using a gradient of SCX 
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buffer B (SCX A containing 1 M potassium chloride) of 0–30% over 30 min. 
Fractions were collected manually at 60 s intervals. SCX fractions containing peptides 
were dried to completeness and dissolved in 30 μl of RP buffer A (2% acetonitrile) 
before separating further using an Ultimate 3000 chromatography system connected 
to a Probot fraction collector (Dionex, Sunnyvale, CA, USA). Samples were 
randomised and loaded onto a C18 trapping column before eluting onto a 75 μm 
internal diameter C18 PepMap column. Peptides were washed for 15 min in RP buffer 
A before eluting with a 2–50% gradient of acetonitrile over 120 min, followed by 
further elution with 90% acetonitrile for 15 min. Eluted peptide fractions were spotted 
onto a MALDI-MS target plate every 10 s with 3 mg/ml α-cyano-2-hydroxy cinnamic 
acid at a flow rate of 1.2 μl/min. A blank injection was performed between peptide 
runs to minimise sample carry-over.  
 
Peptides were analysed using an Applied Biosystems 4800 Proteomics Analyser with 
close external standards to calibrate the instrument. Survey spectra were collected 
from the range 900 to 4000 Da, with a focus mass of 2500 Da. Fifty shots were fired 
per sub-spectrum, with 1000 total shots per spectrum without stop conditions. All sub-
spectra were accepted, and laser intensity was set to 3750. For product ion analysis, a 
maximum of 10 precursor ions per spot were selected automatically with a minimum 
signal-to-noise ratio of 40. Lowest-intensity precursors were acquired first.  
 
An automated database search was run using GPS Explorer v3.6 (AB Sciex, 
Framingham, MA, USA). MASCOT was used as the search engine to search the 
NCBI non-redundant database version Oct 04, 2011, using the following search 
parameters: species = mammals; precursor ion mass tolerance of 150 ppm; MS/MS 
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fragment ion mass tolerance of 0.3 Da; iTRAQ fragment ion mass tolerance of 0.2 
Da. Oxidation of methionine residues were allowed as variable modifications, and N-
term (iTRAQ), lysine (iTRAQ) and MMTS modification of cysteine residues were set 
as fixed modifications. Protein were identified on the basis of having at least one 
peptide with an ion score above 95% confidence. All identified CSF proteins were 
subjected to functional analyses using PubMed search 
(https://www.ncbi.nlm.nih.gov/pubmed/) and the PANTHER classification system 
(http://www.pantherdb.org/genes/batchIdSearch.jsp) [13]. Only peptides unique for a 
given protein was considered for relative quantification. iTRAQ Ratios were 
normalized using the following formula: iTRAQ Ratio = Ratio/(median iTRAQ Ratio 
of all found pairs) that was applied in GPS Explorer software.  
 
2.4. Enzyme-linked immunosorbent assay (ELISA) 
Experiments were performed using commercially available ovine protein ELISA kits: 
sheep haptoglobin (HP), sheep neuroendocrine protein 7B2 (MyBioscience, San 
Diego, CA,   USA), according to the manufactory instructions. The target protein 
concentrations in CSF were determined according to the standard curve with known 
concentrations of the target proteins.  
 
2.5. Western Immunoblotting  
CSF samples (15 l) were mixed with equal amount of 2x Laemmli sample buffer 
(Sigma-Aldrich, St. Louis, Missouri, USA). The samples were loaded onto precast 
10% SDS–polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA) and were 
electrophoresed at 60 mV constant voltage until the dye front reached the bottom of 
the gel. The electrophoresed protein was transferred onto a 0.45 m thick 
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nitrocellulose membrane, which was saturated for 1 h with 5% (w/v) milk powder in 
tris-buffered saline (TBS) containing 0.05% Tween 20 (TBS-T). Membranes were 
then incubated with the primary antibodies rabbit anti-sheep mu chain (1:500)(Sigma-
Aldrich,  St. Louis, Missouri, USA), anti-sheep IgG (1:500)(Zymed-Thermo Fisher 
Scientific, Waltham, Massachusetts, USA); or anti-human haemoglobin β/γ/δ (H-76) 
(1:200)(Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4 °C. 
Thereafter the membranes were washed and incubated with horseradish peroxidase-
conjugated goat anti-rabbit IgG (1:1000)(Dako-Agilent technologies, Santa Clara, 
California, USA). After final wash, the immunostained proteins were developed using 
a Pierce ECL developing kit (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA), and were detected by a Fluorchem M image system (ProteinSimple, San Jose, 
California, USA). A CSF sample was used as an internal standard for each Western 
blotting experiment. The Western bolts images were analysed using Image studio lite 
version 5.2 software (LI-COR Biosciences, Lincoln, Nebraska, USA). Each band was 
analysed by manually selecting them to obtain the density measurement. The ratios of 
the sample density to the internal reference were used and compared among age 
groups.  
 
2.6. Data Analysis 
All values were expressed as mean  SEM. One way ANOVA with Tukey post-hoc 
study was used to analyse comparisons among the 3 age groups. SPSS version 19 
(SPSS INC., Chicago, USA) was used for the analysis. Values of P < 0.05 were 
considered statistically significant, and values of P < 0.01 were considered 
statistically highly significant.  
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3. RESULTS 
 
3.1. Identification of proteins in CSF 
The total protein concentration in the CSF increased with advancing age, as these 
sheep showed age-related reduction in CSF secretion / turnover [10]. We therefore 
applied equal amount volume of CSF in the analysis instead of using equal amount of 
CSF proteins. Two hundred and thirty one peptides were detected from the pooled 
CSF samples. All but 5 of the peptides were named. From these peptides, 143 proteins 
were identified. Of these proteins, 78 were identified with at least two peptides while 
the reminder was identified with a single peptide (Supplement 1 and 2). These 
proteins included not only relatively abundant proteins, such as albumin, IgG, 
transthyretin, transferrin, haptoglobin, complements, and various apolipoproteins, but 
also lower abundance peptides such as neuropeptide Y (see Supplement 1 and 2). The 
functional classification of the 143 identified proteins was listed in Table 1.   
 
3.2. Quantitative analysis of CSF proteins in different age groups 
iTRAQ not only identifies CSF proteins but also enable us to quantitatively compare 
the proteins with different labels [14]. Although the protein profile in each iTRAQ 
experiment may vary when complex protein mixture are analysed, quantitative 
comparison is valid when the same peptide is detected in samples at the same time. 
We therefore compared the ratios of an individual age group to the pooled CSF group. 
Our results demonstrated that there were substantial quantitative differences in many 
proteins between the three groups. We separated these proteins into 2 main groups: 
whose levels have increased (Table 2) or decreased (Table 3) greater than 25%. There 
were 52 proteins with >25% increase in concentrations in the old sheep compared to 
the young (Table 2). 33 of them increased >25% but <50% [e.g. insulin like growth 
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factor binding proteins (IGFBPs), Complements], 13 increased >50% but <1 fold [e.g. 
transthyretin (TTR), apolipoprotein C-III), 6 increased >1 fold [i.e. haptoglobin (Hp), 
haemoglobin (HGB), neuroendocrine protein 7B2, immunoglobin M (IgM), fibrous 
sheath interacting protein 1, vimentin] (Table 2). There were 18 proteins with >25% 
decrease in concentrations in the old sheep compared to the young. 17 of them 
decreased >25% but <50% (e.g. fibrinogen, transferrin), and histone deacetylase 7 
(HDAC7) was gradually decreased for over 80% (Table 3). Glutathione S-transferase 
was decreased in middle aged CSF compared to both young and old CSF. 
   
3.3. Validation of proteins associated with ageing process 
To confirm peptide-based protein identifications and variant proteins as suggested by 
tandem MS, ELISA and Western Immunoblotting were performed on the CSF 
samples.  As the first step towards verifying these ageing biomarkers in Table 2, that 
displayed more than 1 fold among the 3 age groups, all commercially available 
antibodies and ELISA kits for the sheep proteins were purchased for further analysis. 
These were sheep Hp ELISA kit, sheep neuroendocrine protein 7B2 ELISA kit, anti-
sheep mu chain and sheep IgG antibodies. In addition, an antibody for human 
haemoglobin β/γ/δ (H-76) was bought as there were no specific antibodies for sheep 
haemoglobin.  Specific ovine protein ELISA kits indicated there were significant 
increase of Hp and neuroendocrine protein 7B2 in the old CSF (Fig 1). Western blots 
of sheep mu chain showed significant increase in IgM in old CSF, in contrast, there 
were no changes in IgG among age groups (Fig 2). There were no bands on Western 
immunoblots with the anti-human haemoglobin β/γ/δ antibody on the ovine CSF 
samples (data not shown).  
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4. DISCUSSION 
 
In this study, we studied ovine CSF proteome and compared CSF protein levels 
between different ages. We identified 143 different ovine CSF proteins using MS/MS 
fragmentation ions for sequencing, and generated the most complete characterization 
of ovine CSF proteome to date according to our knowledge. The number of proteins 
detected in ovine CSF was similar with in bovine CSF [15], but was lower compared 
to human CSF proteome [16], probably because both the ovine and bovine protein 
database are far less than completed than the human [17]. A large percentage of ovine 
CSF proteins (21.7%) are binding proteins, including the major CNS apolipoproteins 
(e.g. A, C, D, E), consistent with CSF “sink action” [1]. We did not find the 
apolipoprotein B, the major apolipoprotein in the blood that is not present in CSF, 
indicating the minimal blood contamination in our CSF samples [18,19]. To 
maximize efficient use of the MS, 7 ovine CSF samples with same age were pooled 
into a group, similar to our previous studies [12]. This approach will ensure adequate 
materials to identify low abundant proteins and minimized inter-subject variability, 
which was kept in minimum as the sheep was carefully controlled over their age, 
gender, disease states, season etc. The variability can be further addressed by 
performing careful follow-on / validation of aliquot from each individual animal.  
 
Using iTRAQ reporter ion intensities at m/z114, 115, 116, 117, 52 proteins were 
found to be increased for more than 25% between ages, and 6 of them 
(neuroendrocrine protein 7B2, IgM, fibrous sheath interacting protein 1, Hp, HGB, 
vimentin) were gradually increased for more than one fold with age. There were 18 
proteins with >25% decrease in concentrations between ages, and the HDAC7 
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gradually decreased in concentrations for more than 80%. GST decreased in middle 
aged CSF samples compared to both young and old CSF samples.  
 
While high throughput proteomic analysis of CSF proteins selects candidate proteins 
for further study, candidate proteins identified by this approach need to be validated 
before their biological roles are pursued extensively. As the first step towards 
developing candidate ageing markers, we sought to use commercially available 
antibodies against the candidate proteins on individual ovine CSF samples. We used 
as much as possible of commercially available sheep protein diagnosis kits/antibodies, 
and validated 3 candidate proteins: Hp, neuroendocrine secretory protein 7B2 and 
IgM. 
 
Hp is an acute-phase protein that scavenges HGB in the event of haemolysis, but also 
can be induced by inflammation [20, 21]. Human CSF Hp has a role in the protection 
of the CNS against autoimmune inflammatory responses after aneurysmal subarachnoid 
haemorrhage [22]. Increased human CSF Hp concentration were found in a number of 
neurological diseases, e.g. idiopathic normal pressure hydrocephalus, traumatic brain 
injury, Gullain-Barre syndrome and neuromyelitis optica [23, 24].  Chamoun et al. 
[25] reported there was an increased likelihood of detecting Hp in human CSF with 
age and suggested Hp was a marker of BCSFB dysfunction.   
 
Neuroendocrine secretory protein 7B2 resides in the secretory granules of 
neuroendocrine cells and functions as a specific chaperone for the proprotein 
convertase 2 [26] as well as an anti-aggregation secretory chaperone associated with 
neurodegenerative diseases [27]. The normal concentration of 7B2 in human CSF is 
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10-100 folds greater than in plasma [26, 28], suggesting 7B2 is originated from the 
brain.  
 
The brain has historically been considered an ‘immune privileged region’, as it is 
separated from peripheral circulation by BBB and BCSFB. However, the brain also 
contains microglia, the counterpart to macrophages which actively surveys the brain 
[29]. A recent study suggests that brain immune surveillance communicates with the 
immune system and can generate adaptive immune responses [30]. In our study, 
13.3% identified CSF proteins were immunoproteins, which are proteins with 
immunological activities, e.g.  immunoglubins and complements. Among them, IgM 
significant was increased in the old ovine CSF. IgM plays an important role in 
cytolytic reactions and agglutination [31], and is strongly related with a fatal 
neurodegenerative disease called prion disease [32]. There was a correlation between 
CSF IgM and CSF apolipoproteins in patients with neurological diseases [33]. In 
contrast, IgG levels in the CSF were not different between different age groups. IgM 
is the largest antibody and moves out of the brain only with CSF clearance, while IgG 
is the most abundant but the smallest antibody and moves out of the brain via 
additional efflux system [34]. The increase of IgM in the old CSF could be caused by 
either the old sheep were subjected to some infections that the young sheep were not, 
and / or the old sheep had slower CSF turnover rates compared to the young ones -
[10]. 
 
The HGB expression in vertebrates was previously thought to be restricted to red 
blood cells, however the expression of HGB was found in both rat and human neurons 
[35, 36] and HGB was detected in the CSF of normal human controls [37]. HGB was 
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involved in neuronal mitochondrial energetics with epigenetic changes to histones and 
may provide neuroprotection in multiple sclerosis by supporting neuronal metabolism 
[38].  Although the sequence homology of haemoglobin β in ovis aries vs. human is 
83% homology, Western blots with an anti-human haemoglobin β/γ/δ (H-76) 
antibody showed no reaction with the ovine CSF samples.  
 
To our best knowledge, there are only 2 studies on ageing CSF biomarkers in human. 
Utilising a shotgun proteomics strategy in conjunction with ICAT (isotope-coded 
affinity tags), Zhang et al. [18] identified 312 different CSF proteins, of which 187 
were identified with at least two peptides while the reminder was identified with a 
single peptide. The authors discovered 6 proteins that were changed more than one 
fold between the young and old human CSF, i.e. agrin, bromodomain, splice isoform 
-2 of P36873, protein phosphatase, hypothetical protein, serine/threonine protein 
phosphatase, ubiquinol-cytochrome c reductase. An important issue in Zhang’s study 
is that the changes in the relative amount of proteins were measured with pooled CSF 
samples. The variability between humans is more than between sheep. The study 
could not define if the age-related difference found were due to difference in some 
individuals or being distributed over all participants. Although follow up 
immunoassays can partially address this problem, this approach is limited by 
availability of sufficiently sensitive antibodies. Another study on age-related changes 
in human CSF proteome was conducted by Baird et al. [19] using the Slow off-rate 
modified Aptamer Array technique. Baird et al. identified 82 proteins that were 
changed over age 28-82, most of which are associated with immune system activation 
or response to injury. These biomarkers overlap with our discovery in 
immunoproteins, indicating a role for inflammatory process in CNS ageing. A recent 
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study found in healthy ageing human CSF, there was a three-fold increase of soluble 
triggering receptor expressed on myeloid cell 2 (TREM 2), which  functions in 
immune response and may be involved in chronic inflammation [39].  
 
Ageing is associated with chronic inflammation. Inflammageing describes the close 
relationship between low-grade chronic inflammation and ageing in various organs, 
including the brain [40].  A number of theories have been developed to define the 
inflammageing, such as redox stress, mitochondrial damage, immunosenescence, 
endocrinosenescence, epigenetic modification etc [41]. The age-related changes in the 
brain including the inflammageing may provide a substrate for developing 
neurodegenerative disease. Indeed, inflammation has long been associated with 
neurodegenerative diseases [42]. Future studies on neurodegenerative diseases should 
consider the ageing factor.  An important precondition for discovering CSF 
biomarkers in neurodegenerative diseases is an understanding of the dynamic nature 
of the CSF proteome during normal ageing process.  
 
A number of Alzheimer’s disease (AD) biomarkers, such as amyloid beta, tau, 
neurofilament light, were detected in ovine CSF. Total tau and neurofilament light 
levels were comparable with human levels [43]. We also found a few of AD related 
proteins in the ovine CSF, e.g. Apolipoprotein E, Amyloid beta A4 protein isoform b 
precursor, amyloid precursor-like protein 1, and they were not significantly different 
in concentrations among the age groups. Sheep are not known to develop AD 
naturally, probably due to their shorter lifespan compared to humans and being culled 
once past their useful lifespan for the farmers [43]. 
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In conclusion, this study has generated detail knowledge of the ovine proteome and 
presented a number of suitable candidate proteins for further study in terms of their 
physiological variation in CSF during ageing. It would be important to validate the 
results of this study in CSF from humans in future and to conduct further experiments 
to understand their roles in healthy ageing and neurodegerative diseases. Changes in 
the CSF proteins during ageing without disease may be small and heterogeneous 
between individuals. Thus a combination of a number of studies on CSF ageing 
biomarkers would provide a full picture of ageing related changes in CSF proteome. 
A common ageing CSF biomarker identified to date is immunoproteins indicating a 
role of the immune response and inflammation in normal ageing process in the brain. 
MS analysis usually serves to identify candidates, functional and follow up studies 
will be needed for understanding the physiology of brain ageing as well as for 
recognizing neurodegenerative disease-associated changes in CSF proteome patterns.  
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Table 1. Functional classification of ovine CSF proteins 
 
Protein function group Protein number Percentage (%) 
Binding proteins 31 21.7 
Peptide hormones 14 9.8 
Enzymes for metabolism/signalling  36 25.2 
Structural molecules 23 16.1 
Immunoproteins 19 13.3 
Coagulation proteins 9 6.3 
Unknown 11 7.7 
Total 143 100 
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Table 2: A list of proteins showing more than 25% age-related increase in ovine 
CSF 
Protein name Accession 
number 
Peptide 
count 
Average 
iTRAQ 
ratio 
young/IS 
Average 
iTRAQ 
ratio 
middle-
age/IS 
Average 
iTRAQ 
ratio 
old/IS 
% 
increase 
Haptoglobin gi|258499 3 0.57 [3] 0.51 [3] 1.56 [3] Age-
related  
increase 
>1 fold 
gi|998960 1 0.43 [1] 0.39 [1] 1.44 [1] 
Haemoglobin gi|122686 
beta subunit 
3 0.49 [3] 1.06 [3] 1.90 [3] 
gi|1787 
alpha subunit 
1 0.95 [1] 1.56 [1] 1.88 [1] 
Vimentin gi|21757045 2 0.47 [2] 0.44 [2] 1.06 [2] 
IgM (Ig mu chain) gi|165945 2 0.56 [2] 0.61 [2] 1.21 [2] 
Neuroendrocrine 
protein 7B2 isoform 1 
gi|221139785 
 
1 1.17 [1] 1.83 [1] 2.50 [1] 
Fibrous sheath 
interacting protein 1 
gil28175039 1 0.23 [1] 0.34 [1] 0.78 [1] 
Transthyretin gil57526651 7 0.63 [11] 0.73 
[11] 
1.09 
[11] 
Age-
related  
increase 
>50% 
but <1 
fold 
Serpin A3-1 gil31340900 4 0.73 [5] 0.63 [5] 1.28 [5] 
Apolipoprotein C-III gil47564119 3 0.74 [3] 1.09 [3] 1.22 [3] 
Inter-alpha-trypsin 
inhibitor 
gil59857769 2 0.95 [2] 1.16 [2] 1.57 [2] 
gil48374067 2 0.82 [2] 1.12 [2] 1.68 [2] 
Actin gil929752 1 0.78 [1] 0.82 [1] 1.55 [1] 
Calcium uniporter 
channel 
gil833995 1 1.28 [1] 0.88 [1] 2.36 [1] 
Thyroxine-binding 
globulin 
gil155369640 1 0.66 [1] 0.62 [1] 1.07 [1] 
Beta-actin-like protein 
2-like 
gil57043600 1 0.78 [1] 0.82 [1] 1.55 [1] 
Retinoic acid receptor 
responder protein 2 
gil346716116 1 0.58 [1] 0.97 [1] 0.91 [1] 
Neuropeptide Y gil30923117 1 0.78 [1] 1.4 [1] 1.54 [1] 
Pyruvate kinase 
isozymes m1/m2 
isoform 
gil33286418 1 1.05 [1] 0.59 [1] 1.61 [1] 
Serum 
paroxonase/arylesterase 
1 
gil126722853 1 0.99 [1] 0.91 [1] 2.18 [1] 
Complement C1r-B gil164518925 1 0.91 [1] 0.91 [1] 1.44 [1] 
Ceruloplasmin gil57617174 14 0.85 [17] 0.84 
[17] 
1.15 
[17] 
Age-
related  
increase 
>25% 
but 
<50% 
Clusterin gil27806907 7 0.81 [9] 0.93 [9] 1.10 [9] 
IGF-2 gil57164331 2 0.83 [2] 1.43 [2] 1.20 [2] 
IGFBP-2 gil57164237 7 0.90 [7] 1.14 [7] 1.25 [7] 
IGFBP-4 gil27807009 1 0.59 [1] 0.82 [1] 0.76 [1] 
IGFBP-5 gil263306 1 1.69 [1] 1.32 [1] 2.19 [1] 
IGFBP-6 gil56849568 1 0.39 [1] 0.72 [1] 0.82 [1] 
gil5705897 1 0.79 [1] 1.13 [1] 0.96 [1] 
IGFBP-7 gil4504619 3 0.75 [3] 0.61 [3] 1.01 [3] 
Beta 2-microglubin gil57164311 4 0.91 [4] 0.99 [4] 1.17 [4] 
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Primary amine oxidase gil30794300 3 0.75 [3] 0.91 [3] 1.06 [3] 
Complement C4 
 
gil1227 7 0.84 [7] 0.96 [7] 1.06 [7] 
gil1235 5 0.76 [5] 0.91 [5] 1.06 [5] 
gil50567362 4 0.87 [4] 1.08 [4] 1.14 [4] 
gil1314244 1 0.96 [1] 1.52 [1] 1.64 [1] 
Complement C3 gil4093220 1 0.76 [1] 0.96 [1] 1.03 [1] 
Complement C6 gil47115536 1 0.76 [1] 1.20 [1] 0.98 [1] 
Complement C8 gil841248 1 0.61 [1] 0.73 [1] 0.78 [1] 
Chromogranin B gil12644006 2 1.00 [2] 1.28 [2] 1.32 [2] 
Alpha-macroglubin gil290543549 2 0.78 [2] 0.92 [2] 1.17 [2] 
Beta-2 glycoprotein 1 gil54792721 2 0.79 [3] 1.01 [3] 1.06 [3] 
gil57528174 2 0.65 [2] 0.81 [2] 1.14 [2] 
Plasminogen gil833995 2 0.89 [2] 0.87 [2] 1.12 [2] 
gil51702791 1 0.83 [1] 0.99 [1] 1.12 [1] 
Proactivator 
polypeptide 
gil27806447 2 0.60 [2] 0.76 [2] 0.83 [2] 
Apolipoprotein D gil348582766 1 0.71 [1] 0.99 [1] 0.90 [1] 
Brain-type 
ribonuclease 
gil2381819 1 0.82 [1] 1.37 [1] 1.22 [1] 
Extracellular 
superoxide dismutase 
gil130508829 1 0.54 [1] 0.85 [1] 0.72 [1] 
Phosphatidylcholine 
sterol acyltransferase 
gil21542351 1 1.10 [1] 0.90 [1] 1.62 [1] 
Eukephalin gil223387 1 0.86 [1] 1.07 [1] 1.10 [1] 
Neuroserpin gil18158628 1 0.43 [1] 0.66 [1] 0.58 [1] 
Alpha-2 antiplasmin gil27807209 1 0.58 [1] 0.72 [1] 0.82 [1] 
Niemann-pick C2 
protein 
gil28373999 1 0.74 [1] 0.71 [1] 0.94 [1] 
Rheumatoid factor Fab gil3659940 1 1.07 [1] 1.42 [1] 1.60 [1] 
Neuroblastoma 
suppressor 
gil13928832 1 1.04 [1] 1.07 [1] 1.35 [1] 
Malate dehydrogenase gil5174539 1 0.75 [1] 0.72 [1] 0.99 [1] 
Alpha-1 antiproteinase gil461443 1 0.28 [1] 0.28 [1] 0.40 [1] 
Kininogen-1 gil57109938 1 0.74 [1] 0.97 [1] 1.11 [1] 
Fibromodalin gil453157 1 0.78 [1] 0.84 [1] 0.91 [1] 
Column headings refer to the following: accession number is the reference for each 
protein in the NCBInr database; peptide count refers to the number of unique peptides 
with MS/MS ion scores used for protein identification; the average iTRAQ ratios are 
shown after data normalisation followed by the number of peptides used for 
quantification in square brackets. IS = internal standard.  
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Table 3: A list of proteins showing more than 25% age-related decrease in ovine 
CSF 
Protein name Accession 
number 
Peptide 
count 
Average 
iTRAQ 
ratio 
young/IS 
Average 
iTRAQ 
ratio 
middle-
age/IS 
Average 
iTRAQ 
ratio 
old/IS 
% 
decrease 
Histon 
deacetylase 7 
 
gi|30913010 1 3.85 [1] 1.39 [1] 0.76 [1] Age-
related  
decrease 
>80%  
Fibrinogen  gil1346006 3 1.25 [3] 1.40 [3] 0.74 [3] Age-
related  
decrease 
>25% but 
<50% 
gil3789962 3 1.03 [3] 1.15 [3] 0.87 [3] 
gil6980816 2 1.23 [2] 1.42 [2] 0.92 [2] 
Neurosecretory 
protein VGF 
gil17136078 2 1.39 [2] 1.04 [2] 0.99 [2] 
Beta-1,3-N-
actyl 
glucosamingl 
transferase 6  
gil61553937 
 
2 1.64 [2] 1.38 [2] 1.17 [2] 
Tetranectin gil37409 2 1.23 [2] 1.37 [2] 0.83 [2] 
Transferrin gil2318026 2 1.40 [2] 1.09 [2] 0.98 [2] 
Calreticulin gil545920 2 0.95 [2] 1.11 [2] 0.64 [2] 
gil237420 1 0.91 [1] 0.99 [1] 0.55 [1] 
Contactin-2 gil4827022 2 1.25 [2] 0.73 [2] 0.77 [2] 
V-set and 
transmembrane 
domain protein 
2A 
gil20306326 1 1.12 [2] 0.81 [2] 0.59 [2] 
Cadherin-15 gil4826669 1 1.39 [1] 0.89 [1] 0.72 [1] 
Chain A, 
Divalent cation 
tolerant protein 
cuta 
gil56554578 1 1.37 [1] 1.04 [1] 1.00 [1] 
Cell adhesion 
molecule 4 
gil21686977 1 1.11 [1] 0.50 [1] 0.77 [1] 
Adipsin / 
complement 
factor D 
gil773265 1 1.50 [1] 1.27 [1] 1.09 [1] 
Nidogen-2 gil2791962 1 1.35 [1] 1.22 [1] 0.70 [1] 
Protein C  gil163487 1 0.93 [1] 0.68 [1] 0.69 [1] 
Neurocan core 
protein 
gil77681353 1 1.11 [1] 0.71 [1] 0.61 [1] 
Protein kinase 
C-binding 
protein NELL-2 
gil2494290 1 1.81 [1] 1.40 [1] 1.00 [1] 
Nuclear factor 
of activated T 
cells 
cytoplasmic 
isoform 2  
gil27886541 1 0.96 [1] 1.56 [1] 0.38 [1] 
Column headings refer to the following: accession number is the reference for each 
protein in the NCBInr database; peptide count refers to the number of unique peptides 
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with MS/MS ion scores used for protein identification; the average iTRAQ ratios are 
shown after data normalisation followed by the number of peptides used for 
quantification in square brackets. IS = internal standard.  
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Figure 1. Concentration of haptoglobin (HP) and neuroendocrine protein 7B2 in CSF 
of young, middle age, and old groups by ELISA assay.  A, C are standard curves of 
Hp (A) and neuroendocrine 7B2 (C); B and D summarized the concentrations of Hp 
(B) and neuroendocrine 7B2 (D) in CSF from different age groups, n = 7. *compared 
to young group, P<0.01. 
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Figure 2. Relative amount of IgM (A) and IgG (C) in CSF between different ages, 
which was based on their band density of Western immunoblotting image of IgM (B) 
and IgG (D) respectively. In image B or D, lanes 1-4: young CSF; lanes 5-7: middle 
aged CSF; lanes 8-10: old CSF; lane 11: molecular size marker. *compared to young 
group, P<0.01  
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